@article{article_1064260, title={Abciximab-induced thrombocytopenia: correct management}, journal={Deneysel ve Klinik Tıp Dergisi}, volume={39}, pages={581–583}, year={2022}, author={Kelkitli, Engin and Odabaşı Giden, Aslı and Deniz Kürekçi, Derya and Turgut, Mehmet}, keywords={Abciximab, glycoprotein IIb/IIIa receptor inhibitors, side effect, thrombocytopenia}, abstract={Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.}, number={2}, publisher={Ondokuz Mayıs University}